NBY
- NovaBay Pharmaceuticals, Inc.
()
Overview
Company Summary
NovaBay Pharmaceuticals, Inc. (NBY) is a biopharmaceutical company focused on developing and commercializing innovative antimicrobial products. The company specializes in non-antibiotic, topical products that aim to address unmet needs in dermatology, ophthalmology, and urology.
In the dermatology field, NovaBay's flagship product is Avenova�, a prescription eyelid and eyelash hygiene solution. Avenova is designed to help manage the symptoms of various ocular conditions, including blepharitis and meibomian gland dysfunction. These conditions are associated with bacterial colonization and can lead to discomfort, inflammation, and dryness of the eyes. Avenova's formulation contains pure hypochlorous acid, a naturally occurring antimicrobial substance, which helps to eliminate harmful bacteria while being gentle on the delicate eye area.
NovaBay also offers NeutroPhase�, a solution used for the irrigation and cleansing of acute and chronic wounds. NeutroPhase's formulation includes pure, stable, and gentle hypochlorous acid, which helps in the cleaning and debridement of wounds while promoting a favorable healing environment.
In the urology field, NovaBay's product portfolio includes CelleRx�, a proprietary bladder instillation for the treatment of urinary catheter blockage and encrustation (UCBE). UCBE is a common problem in patients who require long-term urinary catheterization, resulting in discomfort, urinary tract infections, and potentially serious complications. CelleRx is designed to prevent and dissolve blockages, improving the patient's quality of life.
NovaBay Pharmaceuticals focuses on developing products that offer effective and safe alternatives to traditional antibiotics. By harnessing the power of hypochlorous acid, the company aims to address the challenges posed by antibiotic resistance and provide solutions for various dermatological, ophthalmological, and urological conditions.